About us
About us
Join us
Contact us
Corporate social responsibility
Code of conduct
Amryt compliance
Aegerion Consent Decree
Patients and carers
Patients and carers
Homozygous familial hypercholesterolaemia
Lipodystrophy
Epidermolysis bullosa
Acromegaly
Advocacy
Healthcare professionals
Healthcare professionals
Our science
Trials and registries
Expanded access programme
Medical information enquiries
Grants and donations
Product portfolio
Product portfolio
Juxtapid
®
/ Lojuxta
®
▼
Myalept
®
/ Myalepta
®
▼
Mycapssa
®
Pipeline
Report adverse event
Newsroom
Investors
The Company
News
Reports and presentations
Stock information
Events
Corporate governance
AIM Delisting
Contingent Value Rights (CVR) FAQ
Analysts
Contacts and advisors
Business development
About us
About us
Join us
Contact us
Corporate social responsibility
Code of conduct
Amryt compliance
Aegerion Consent Decree
Patients and carers
Patients and carers
Homozygous familial hypercholesterolaemia
Lipodystrophy
Epidermolysis bullosa
Acromegaly
Advocacy
Healthcare professionals
Healthcare professionals
Our science
Trials and registries
Expanded access programme
Medical information enquiries
Grants and donations
Product portfolio
Product portfolio
Juxtapid
®
/ Lojuxta
®
▼
Myalept
®
/ Myalepta
®
▼
Mycapssa
®
Pipeline
Report adverse event
Newsroom
Investors
The Company
News
Reports and presentations
Stock information
Events
Corporate governance
AIM Delisting
Contingent Value Rights (CVR) FAQ
Analysts
Contacts and advisors
Business development
Sitemap
Pages
About us
Corporate Social Responsibility
Accessibility
Advocacy
Aegerion Consent Decree
Amryt Compliance
Business development
Contact us
Cookie policy
Fraud warning
Healthcare Professionals
Expanded access programme
Grants and donations
Medical Information Enquiries
Medical Information Enquiries Brazil
Medical Information Enquiries Brazil (EN)
Home
Investors
AIM Delisting
AIM Rule 26
Analysts
Circulars and admission document
Contacts and Advisors
Contingent Value Rights (CVR) FAQ
Corporate Governance
Events
Reports
Register for email alerts
Share price information
Join us
Newsroom
Our science
Trials
Trials
Patient Stories
Patients and carers
Acromegaly
Acromegaly
Epidermolysis Bullosa
Epidermolysis Bullosa
Homozygous Familial Hypercholesterolaemia
Lipodystrophy
Lipodystrophy
Pipeline
Privacy
Product Portfolio
Juxtapid
®
/ Lojuxta
®
▼
Myalept
®
/ Myalepta
®
▼
Mycapssa
®
Oleogel-S10 (birch triterpenes)
Sitemap
Social Media Guidelines
Terms and conditions
Amryt Pharma has been acquired by Chiesi Farmaceutici S.p.A.
View the press release to learn more
.
CLOSE